NS

Navin Satyapal Saxena

Active Director Director DIN 00109583
DIN 00109583 First appointment Mar 1994 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 8 active board seats
Total affiliations 8 Since Mar 1994
Shareholding value •••• Premium profile

About Navin Satyapal Saxena

Data last updated:

Navin Satyapal Saxena is a Director at Rusan Pharma Limited (since 1994), Director at Rusan Health Care Private Limited (since 1999) and Director at Navin Saxena Research And Technology Private Limited (since 1994), and holds 5 more current directorships. The companies operate in Pharma, Healthcare and Financial Services. The 8 current companies with reported revenue have a combined latest revenue of ₹440 Cr; the largest is Rusan Pharma Limited at ₹392 Cr (FY 2025).

DIN 00109583
Primary Designation Director
Industry Pharma
First Appointment 15 Mar 1994
Oldest Company Age 32 yrs
Largest company Rusan Pharma Limited · ₹392 Cr (FY 2025)
Combined revenue ₹440 Cr across 8 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rusan Pharma Limited U24230MH1994PLC077069
Director15 Mar 19941994₹392 Cr (FY 2025)Active
Rusan Health Care Private Limited U24200MH1999PTC122536
Director03 Nov 19991999₹31.60 Cr (FY 2024)Active
Director23 Nov 19941994₹13.34 Cr (FY 2025)Active
Quantys Clinical Private Limited U74120MH2014PTC257021
Director08 Aug 20142014₹1.56 Cr (FY 2025)Active
Navicare Pharma Private Limited U24110MH2011PTC216977
Director03 May 20112011₹62.6 Lakh (FY 2024)Active
Tuscany Holdings Private Limited U65990MH1994PTC081494
Director17 Oct 20121994₹26.9 Lakh (FY 2025)Active
Director06 Sep 20222022₹5 Lakh (FY 2025)Active
Director23 Jan 19981998₹1.6 Lakh (FY 2024)Active

Directorship timeline

Open interactive timeline →
Navicare Pharma Private Limited
Rusan Health Care Private Limited
Rusan Pharma Limited
Euromed International Private Limited
Premium access

Shareholding and investment profile for Navin Satyapal Saxena

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Navin Satyapal Saxena

Navin Satyapal Saxena currently holds 8 directorships: Rusan Pharma Limited (Director, since 15 Mar 1994, revenue ₹392 Cr (FY 2025)); Rusan Health Care Private Limited (Director, since 03 Nov 1999, revenue ₹31.60 Cr (FY 2024)); Navin Saxena Research And Technology Private Limited (Director, since 23 Nov 1994, revenue ₹13.34 Cr (FY 2025)); Quantys Clinical Private Limited (Director, since 08 Aug 2014, revenue ₹1.56 Cr (FY 2025)); Navicare Pharma Private Limited (Director, since 03 May 2011, revenue ₹62.6 Lakh (FY 2024)); and 3 more.

Navin Satyapal Saxena was first appointed on 15 Mar 1994 as Director at Rusan Pharma Limited. The most recent appointment on record is 06 Sep 2022 at Ru-Tech Design Masters Private Limited.

The 8 current companies of Navin Satyapal Saxena that report revenue have a combined latest revenue of ₹440 Cr: Rusan Pharma Limited ₹392 Cr (FY 2025); Rusan Health Care Private Limited ₹31.60 Cr (FY 2024); Navin Saxena Research And Technology Private Limited ₹13.34 Cr (FY 2025); Quantys Clinical Private Limited ₹1.56 Cr (FY 2025); Navicare Pharma Private Limited ₹62.6 Lakh (FY 2024); and 3 more.

The current boards of Navin Satyapal Saxena's companies include Aakarsh Navin Saxena (Rusan Pharma Limited), Balasaheb Annasaheb Patil (Rusan Pharma Limited), Kunal Navin Saxena (Rusan Pharma Limited), Sandeep Verma (Rusan Pharma Limited), Ashok Chaturbhuj Sharma (Rusan Health Care Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available